Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Satellos Bioscience Inc.

News headline image
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in December Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in November Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in Four September Institutional and Retail Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present at Canaccord Genuity’s 45th Annual Growth Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Bioscience Shareholders Elect Two New Board Members
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present at the CureDuchenne FUTURES National Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in Two April Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Reports 2024 Financial Results and Highlights Company Progress
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in Oppenheimer Movers in Rare Disease Summit
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Appoints Stephanie Brown to Board of Directors
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.